Oncology Grand Rounds Series: Part 6 — Emerging Strategies in Non-Small Cell Lung Cancer

Video proceedings from the sixth in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Ms Kelly EH Goodwin, Dr Joel W Neal, Ms Judy Pagtama and Dr Anne S Tsao

1.6 contact hours

To complete the Post-test and Educational Assessment and Credit Form, click here. A statement of CNE credit will be issued for scores of 80% or better. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

Related links:

Home
CNE evaluation
CNE information and faculty disclosures
Select publications
PowerPoint slides

Introduction
Program overview: Dr Love
EGFR-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC)
Case (Ms Pagtama): A man in his late 50s with Stage IV adenocarcinoma of the lung with an EGFR tumor mutation, a right pleural effusion and a single brain metastasis who received first-line osimertinib
Case (Ms Goodwin): A woman in her early 70s with Stage IV adenosquamous NSCLC with an EGFR tumor mutation who was found to have a MET amplification after disease progression on osimertinib
Immune Checkpoint Inhibitor Therapy for Metastatic NSCLC
Case (Ms Pagtama): A man in his mid-90s with Stage IV pan-wild-type adenocarcinoma of the lung and a high PD-L1 tumor proportion score who received pembrolizumab monotherapy
Case (Ms Goodwin): A man in his mid-60s with extensive metastatic adenocarcinoma of the lung who received carboplatin/ pemetrexed/pembrolizumab
Immunotherapy as Consolidation After Chemoradiation Therapy for Locally Advanced NSCLC
Case (Ms Pagtama): A man in his early 70s with locally recurrent adenocarcinoma of the lung who received concurrent chemoradiation therapy followed by consolidation durvalumab